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Abstract
Objective
There is controversy regarding the significance of radiological consolidation in the context
of COPD exacerbation (eCOPD). While some studies into eCOPD exclude these cases,
consolidation is a common feature of eCOPD admissions in real practice. This study aims
to address the question of whether consolidation in eCOPD is a distinct clinical phenotype
with implications for management decisions and outcomes.
Patients and Methods
The European COPD Audit was carried out in 384 hospitals from 13 European countries
between 2010 and 2011 to analyze guideline adherence in eCOPD. In this analysis, admis-
sions were split according to the presence or not of consolidation on the admission chest
radiograph. Groups were compared in terms of clinical and epidemiological features, exist-
ing treatment, clinical care utilized and mortality.
Results
14,111 cases were included comprising 2,714 (19.2%) with consolidation and 11,397
(80.8%) without. The risk of radiographic consolidation increased with age, female gender,
cardiovascular diseases, having had two or more admissions in the previous year, and spu-
tum color change. Previous treatment with inhaled steroids was not associated. Patients
with radiographic consolidation were significantly more likely to receive antibiotics, oxygen
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and non-invasive ventilation during the admission and had a lower survival from admission
to 90-day follow-up.
Conclusions
Patients admitted for COPD exacerbation who have radiological consolidation have a more
severe illness course, are treated more intensively by clinicians and have a poorer prognosis.
We recommend that these patients be considered a distinct subset in COPD exacerbation.
Background
Exacerbation of Chronic Obstructive Pulmonary Disease (eCOPD) is one of the commonest
causes for hospital admission across Europe and is associated with high morbidity and mortal-
ity [1]. Although initially considered to be a single clinical entity, it is increasingly recognized
that the presentation and underlying mechanisms vary [2]. These differing phenotypic presen-
tations of eCOPDmay require specific management approaches [3]. Consolidation on the
chest radiograph has been acknowledged as part of this diversity in the clinical presentation of
exacerbations [4]. Previous analyses have reported that some patients discharged with a pri-
mary diagnosis of eCOPD present with radiographic consolidation [5]. The distinction
between infective and non-infective eCOPD is key, and a major role has been assigned to the
presence of sputum purulence. However, there is still controversy regarding the significance of
radiological consolidation found incidentally in cases clinically diagnosed as eCOPD and
whether eCOPD with a finding of consolidation on the chest radiograph represents a different
disease entity from a full clinical pneumonia in a patient with COPD [6, 7]. This uncertainty
has escalated with major randomised controlled trials in eCOPD tending to exclude patients
with radiographic consolidation [8, 9].
Related to this controversy is the growing evidence that the use of inhaled corticosteroids
(ICS) in patients with COPD is associated with an increased incidence of clinically diagnosed
pneumonia. Secondary analysis of the Towards a Revolution in COPD Health (TORCH) trial
discovered a significantly increased risk of pneumonia in association with inhaled steroid use
[10]. Subsequent studies have also reported a 50–70% increase in pneumonia with inhaled ste-
roid use [11–13].
The 2010–2011 European Audit of COPD admissions collected data on 16018 exacerbations
of COPD in order to investigate adherence to the GOLD guidelines for COPD management
across Europe [14]. Many patients had consolidation on the chest radiograph [5]. This paper
analyses the significance of radiological consolidation in eCOPD in this large population. The
aim is to analyze correlations between radiological consolidation and patient characteristics,
prior treatment, clinical features of exacerbation and inpatient treatment provided and the
impact of consolidation on survival.
Methods
This analysis is based on the findings of the European COPD Audit. This audit was carried out
in 384 hospitals from 13 European countries between 2010 and 2011. The methodology of the
audit has previously been reported in detail [14]. Briefly, consecutive admissions were assessed
over an 8-week period with a second round of data collection for each admission at 90 days to
review late outcomes. Eligibility for inclusion in the audit was a clinician-made diagnosis of
eCOPD at the point of admission which was then confirmed by a senior clinician at the time of
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discharge from hospital. Patients with a primary diagnosis than eCOPD (e.g. Pneumonia) at
discharge were withdrawn from the study cohort and no information was gathered from
excluded cases. The exclusion diagnosis of pneumonia was established by the clinician in
charge, with reference to the whole clinical and radiological presentation. Due to the size of the
audit and its primary function as a non-interventional audit of COPD practices and standards
of care, diagnosis of consolidation was not reviewed by a radiologist as part of a protocol. The
radiography was done upon admission and the description and final interpretation was done
by the senior physician in charge of the case upon discharge, once evaluated the whole clinical
picture. Information on demographics, previous history, clinical data upon admission, data
during admission and information on discharge and follow up was collected on a web-tool
[14]. The European Audit followed the European ethical requirements for scientific studies. All
partners of the project accepted the general ethical rules of the European Respiratory Society,
which funded the project. Since there is no European Ethics Committee for audits, national
societies ensured compliance with European and National ethical requirements [14].
For the present analysis, the admissions were split according to the presence of consolida-
tion on the admission chest radiograph. Cases with other radiological findings which might
influence management or outcomes, including interstitial infiltrates, nodular lesions, pleural
effusions or pneumothorax were excluded from the analysis.
Independent variables were classified in three groups: ‘patient-related’ variables were base-
line factors associated with the subject; ‘exacerbation-related’ variables reflected the clinical
presentation or severity of the current exacerbation, and ‘management-related’ variables were
those concerning the diagnostic and therapeutic measures used before and during the admis-
sion and on discharge.
Data analysis
Clinical variables were presented as the mean with standard deviations or the absolute and rela-
tive frequencies depending on the nature of the variable. Unpaired T-tests and Chi-squared
tests were used to compare continuous and discrete variables respectively between consolida-
tion and non-consolidation groups. Two binomial multivariate logistic regression analyses
were performed. Both used the presence of consolidation as the dependent variable. The first
multivariate analysis looked at the relationship between patient-related, exacerbation-related
or management-related previous to the admission factors and the finding of radiological con-
solidation to investigate factors associated with the presence of this consolidations. The second
looked at the relationship between management-related variables during the admission and the
likelihood of consolidation to investigate if health care provided was different. Variables with a
p value< 0.1 in the bivariate analysis were considered for both models. These statistical com-
putations were performed using the Statistical Package for Social Sciences (SPSS, IBM Corpo-
ration. Somers, NY) version 18.0. The alpha error was set at 0.05.
The relationship between consolidation and time to 90-day mortality was explored by using
Kaplan-Meier curves, with Log-rank test to analyze the survival curve difference between
patients with and without consolidation. To control for all confounders, an additional multi-
level binomial logistic regression analysis [15] was performed to study factors associated with
mortality from admission to 90-day follow-up using Stata 12 (StataCorp LP, Texas, USA). In
this model, two levels were considered: patients at the first level and hospitals at the second
one. These analyses were performed considering that: 1) The multilevel model assumes a hier-
archical data structure with explanatory variables measured at both patient and hospital levels;
and, 2) inter-hospital variation in the dependent variable (mortality) was random. Thus, we fit-
ted a final model that, through a forward selection procedure based on Wald tests results,
Consolidations and COPD Exacerbations
PLOS ONE | DOI:10.1371/journal.pone.0134004 July 27, 2015 3 / 12
added as covariates to the model those explanatory variables associated with mortality in the
bivariate analysis. Because missing data in some explanatory variables was not randomly dis-
tributed, we considered the "missing values" as an additional stratum in the categorization of
those variables. The final model was estimated by maximum likelihood using the adaptive
Gaussian quadrature approximation to the log likelihood with seven quadrature points [16].
Results
19,150 cases were initially considered upon admission as potential cases with a clinician made
diagnosis of eCOPD. The diagnosis of eCOPD was confirmed at discharge review in 16,018
cases (83.6%). Of these, 1,684 cases (10.5%) were excluded due to other significant radiological
findings, 223 (1.3%) for lack of a chest radiograph and 23 cases (0.1%) for lack of information
on the radiographic findings. The final study sample was 14,111 cases. These consisted of 2,714
cases (19.2%) with consolidation and 11,397 cases (80.8%) without.
Baseline features of the included cases are summarized in Table 1. Patients with consolida-
tion were older, had a higher Charlson comorbidity index and more frequent exacerbation
history although these differences were small. Exacerbation-related variables are summarized
in Table 2. Sputum production and purulence were more frequently presenting features in
patients with consolidation. These patients had a higher rate of severe acidosis (pH< 7.30)
and their length of stay was longer than those without consolidation.
The therapeutic interventions before and during the admission and upon discharge are
summarized in Table 3. Bivariate analysis showed no association between radiographic findings
Table 1. Characteristics of the patients included in the study.
Without consolidation (n = 11397) With consolidation (n = 2714) P value*
Age (years) 70.4 (10.8) 71.6 (10.5) < 0.001
Male gender (n) 7699 (67.6) 1784 (65.7) 0.072
Current smokers (n) 3651 (32.0) 795 (29.3) 0.042
Tobacco history (pack-years) 47.8 (30.3) 46.2 (34.7) 0.045
Comorbidities (Charlson) 2.2 (1.5) 2.4 (1.5) < 0.001
Cardiovascular diseases (n) 4345 (38.1) 1237 (45.6) < 0.001
Diabetes (n) 2221 (19.5) 556 (20.5) 0.248
Neoplasms (n) 1227 (10.8) 307 (11.3) 0.411
Body mass index (kg/m2) 26.7 (6.3) 26.6 (6.9) 0.647
Admissions the previous year (n) 1.1 (1.8) 1.2 (1.7) 0.072
Two or more admissions in the previous year (n) 2942 (25.8) 753 (27.7) <0.001
Spirometry: FVC (%) 65.7 (20.3) 65.5 (20.5) 0.781
Spirometry: FEV1 (%) 43.7 (17.3) 44.3 (17.3) 0.266
Spirometric classification:
No spirometry 4476 (39.3) 1241 (45.7) < 0.001
No obstruction 777 (6.8) 216 (8.0) 0.040
FEV1 > 80% 139 (1.2) 32 (1.2) 0.915
FEV1 50–80% 1635 (14.3) 314 (11.6) < 0.001
FEV1 30–50% 2763 (24.2) 580 (21.4) 0.002
FEV1 < 30% 1566 (13.7) 315 (11.6) 0.003
FEV1 missing 41 (0.4) 16 (0.6) 0.093
Data expressed as mean (standard deviation) and absolute (relative) frequencies depending on the nature of the variable.
* p value calculated by Chi-squared test or Student T test for discrete and continuous variables as appropriate.
doi:10.1371/journal.pone.0134004.t001
Consolidations and COPD Exacerbations
PLOS ONE | DOI:10.1371/journal.pone.0134004 July 27, 2015 4 / 12
Table 2. Exacerbation-related variables reflecting the clinical presentation or severity of the exacerbation.
Without consolidation (n = 11397) With consolidation (n = 2714) P value*
Dyspnoea increase (n) 10988 (96.4) 2594 (95.6) 0.121
Sputum increase (n) 7321 (64.2) 1838 (67.7) 0.001
Sputum color change (n) 5675 (49.8) 1536 (56.6) < 0.001
PaO2 (kPa) 8.6 (3.3) 8.5 (3.5) 0.685
PaCO2 (kPa) 6.4 (2.1) 6.4 (2.2) 0.427
Mild acidosis (pH 7.35–7.30) 972 (8.5) 237 (8.7) 0.350
Severe acidosis (pH < 7.30) 735 (6.4) 260 (9.6) < 0.001
Length of stay (days) 8.21 (7.7) 10.04 (9.7) < 0.001
Data expressed as mean (standard deviation) and absolute (relative) frequencies depending on the nature of the variable.
* p value calculated by Chi-squared test or Student T test for independent variables as appropriate.
FVC: forced vital capacity. FEV1: forced expiratory volume in the first second. PaO2: partial pressure of oxygen in arterial blood. PaCO2: partial pressure
of carbon dioxide in arterial blood
doi:10.1371/journal.pone.0134004.t002
Table 3. Management-related variables.
Without consolidation (n = 11397) With consolidation (n = 2714) P value*
Treatments before admission
Short-acting bronchodilators (n) 7451 (65.4) 1810 (66.7) 0.200
Long-acting bronchodilators (n) 5999 (52.6) 1351 (49.8) 0.008
Inhaled corticosteroids (n) 7890 (69.2) 1849 (68.1) 0.268
Systemic corticosteroids (n) 2192 (19.2) 507 (18.7) 0.532
Antibiotics (n) 2324 (20.4) 575 (21.2) 0.355
Methylxanthines (n) 1828 (16.0) 432 (15.9) 0.906
Treatments during admission
Short-acting bronchodilators (n) 10507 (92.2) 2406 (88.7) < 0.001
Inhaled corticosteroids (n) 3736 (33.1) 949 (35.0) 0.060
Systemic corticosteroids (n) 9666 (84.8) 2132 (78.6) < 0.001
Antibiotics (n) 9674 (84.9) 2526 (93.1) < 0.001
Methylxanthines (n) 1543 (13.5) 392 (14.4) 0.226
Diuretics (n) 2840 (24.9) 744 (27.4) 0.008
Oxygen (n) 9687 (86.4) 2366 (88.5) 0.004
Non-invasive MV (n) 1425 (12.5) 458 (16.9) < 0.001
Invasive MV (n) 164 (1.4) 88 (3.2) < 0.001
Home treatments at discharge
Short-acting bronchodilators (n) 7143 (62.7) 1711 (63.0) 0.723
Long-acting bronchodilators (n) 7595 (66.6) 1651 (60.8) < 0.001
Inhaled corticosteroids (n) 9283 (81.5) 2099 (77.3) < 0.001
Systemic corticosteroids (n) 6319 (55.4) 1175 (43.3) < 0.001
Antibiotics (n) 4853 (42.6) 1153 (42.5) 0.931
Methylxanthines (n) 2211 (19.4) 515 (19.0) 0.625
Home oxygen (n) 3740 (32.8) 872 (32.1) < 0.001
Home MV (n) 619 (5.6) 112 (4.3) 0.010
Data expressed as absolute (relative) frequencies.
* p value calculated by Chi-squared test.
doi:10.1371/journal.pone.0134004.t003
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and use of inhaled or oral corticosteroids before the admission. During the admission, patients
with consolidation had a lower rate of systemic corticosteroid treatment and a higher rate of anti-
biotic treatment. Additionally, this group required oxygen therapy and non-invasive mechanical
ventilation (NMV) as well as invasive mechanical ventilation (IMV) more frequently.
The results of the multivariate analysis evaluating factors associated with the presence of
consolidation are summarized in Table 4. The risk of radiographic consolidation increased
with age, female gender, cardiovascular diseases, having had two or more admissions in the
previous year, and sputum color change. Acidosis on admission remained significantly corre-
lated with consolidation.
Factors relating to clinical care provided to patients with consolidation are summarized in
the multivariate analysis in Table 5. Patients with radiographic consolidation were more likely
to receive antibiotics, oxygen and NMV and IMV during the admission. However, these
patients were less likely to have had blood gas analysis on admission or to be treated with
short-acting bronchodilators or systemic steroids.
The relationship with 90-day survival in patients with and without consolidation is depicted
in Fig 1. There was a significant (p< 0.001) difference in the time to death in the two groups
with a mean of 81.3 days (95%CI 80.4 to 82.2) with consolidation and mean 85.0 days (95%CI
84.7 to 85.3) without. Factors associated with mortality are summarized in Table 6. After
adjusting for all potential confounders, consolidation was associated with mortality with an
OR of 1.36 (95%CI 1.20 to 1.55). Cardiovascular, neoplastic and overall comorbidity were asso-
ciated with greater global mortality as was greater FEV1 impairment. Increased BMI and
greater smoking history were associated with lower mortality which are unexpected findings
and may reflect confounding by different levels of comorbidity in these groups. Purulent spu-
tum, which was correlated with consolidation (Table 4), also correlated with increased global
mortality. Mortality was positively associated with use of IMV and greater acidosis which are
both features of more severe exacerbation. The percentage of re-admissions after discharge was
similar for cases with consolidation (36.2%) and cases without (34.7%).
Discussion
Our Findings
A number of small scale studies have compared COPD patients admitted to hospital with exac-
erbations with and without pneumonia. However, the significance of radiological shadowing in
Table 4. Multivariate analysis of baseline factors, previous treatment factors and clinical features versus risk of consolidation.
Crude Adjusted
Odds ratio 95%CI Odds ratio 95%CI
Age (years) 1.011 1.007–1.015 1.010 1.005–1.016
Female gender 1.085 0.993–1.186 1.188 1.059–1.333
Current smokers 0.877 0.800–0.963 0.974 0.861–1.062
Charlson index 1.068 1.040–1.096 1.021 0.981–1.062
Cardiovascular diseases 1.152 1.001–1.326 1.257 1.108–1.429
Two or more admissions in the previous year 1.162 1.055–1.279 1.133 1.008–1.427
Sputum increase 1.192 1.084–1.311 0.972 0.835–1.132
Sputum color change 1.355 1.238–1.482 1.381 1.199–1.591
pH below 7.30 1.620 1.395–1.882 1.624 1.362–1.936
Treatment with long-acting bronchodilators before the admission 0.892 0.820–0.970 0.857 0.765–0.960
Treatment with inhaled steroids before the admission 0.947 0.861–1.043 0.966 0.851–1.096
doi:10.1371/journal.pone.0134004.t004
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the context of a specific clinical diagnosis of eCOPD as opposed to pneumonia remains
unclear. In this study of 14,111 patients prospectively identified and followed for 90 days after
admission, we identified some significant differences in patient characteristics, management
and outcomes between those with and without radiological consolidation. This further clarifies
the significance of incidental radiological consolidation in patients with a discharge diagnosis
of eCOPD.
Consolidation on the chest radiograph was slightly more likely to occur in patients with fre-
quent exacerbations and in older patients with more co-morbid conditions and in females.
There was however considerable overlap between the two groups. There is no correlation
between consolidation and greater spirometric severity of COPD or with pre-admission use of
inhaled corticosteroid therapy. Perhaps the more important correlations were with the pres-
ence of purulent sputum and an arterial pH<7.30 on the admission blood gas.
The significant differences in inpatient management between consolidation and no consoli-
dation groups in our multivariate analysis likely reflect a more severe clinical presentation in
this group. This is supported by the finding of worse acidosis. Patients with radiological consol-
idation were more likely to receive both NIV and IMV and particularly the latter. The use of
IMV across all COPD patients presenting with acidosis is very uncommon indeed [5]. The
greater use of IMV with consolidation, despite these patients being slightly older, suggests that
the presence of radiological consolidation makes the decision to invasively ventilate more likely
as it is perhaps seen as a potentially reversible cause for deterioration. The two-fold higher use
of antibiotics in the consolidation group represents appropriate prescribing given the body of
evidence suggesting a higher rate of bacterial etiology in cases with consolidation [17]. The
increased inpatient and follow up mortality rates in the consolidation group also indicate a
more severe illness. The Kaplan-Meier curve demonstrates that greater mortality in the consol-
idation group occurs both during the admission and throughout the period of follow up.
Comparable Studies
Comparable observational studies into pneumonia in COPD have reported on patient numbers
in the low hundreds [17, 18]. Lieberman et al. compared 23 patients admitted with ‘pneumonic’
Table 5. Multivariate analysis of clinical care provided versus risk of consolidation.
Crude Adjusted
Odds ratio 95%CI Odds ratio 95%CI
Blood gas taken on admission (n) 0.806 0.718–0.904 0.817 0.713–0.935
Treatment with short-acting bronchodilators during the admission 0.662 0.577–0.759 0.748 0.638–0.877
Treatment with inhaled steroids during the admission 1.089 0.997–1.189 1.083 0.983–1.194
Treatment with systemic steroids during the admission 0.656 0.591–0.729 0.716 0.632–0.812
Treatment with antibiotics during the admission 2.393 2.046–2.799 2.587 2.172–3.061
Treatment with diuretics during the admission 1.138 1.035–1.251 1.026 0.925–1.138
Oxygen during the admission 1.215 1.066–1.384 1.347 1.152–1.575
Non-invasive mechanical ventilation during the admission 1.048 1.023–1.073 1.157 1.366–1.807
Invasive mechanical ventilation during the admission 1.039 1.014–1.065 2.163 1.622–2.884
Treatment with long-acting bronchodilators at discharge 0.777 0.713–0.848 0.892 0.810–0.983
Treatment with inhaled steroids at discharge 0.777 0.702–0.860 0.897 0.794–1.012
Treatment with systemic steroids at discharge 0.614 0.564–0.668 0.710 0.644–0.782
Oxygen at discharge 0.987 0.901–1.080 1.014 0.916–1.123
Home mechanical ventilation at discharge 0.760 0.619–0.934 0.529 0.417–0.672
doi:10.1371/journal.pone.0134004.t005
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exacerbations of COPD against 217 with ‘non-pneumonic’ exacerbations differentiated accord-
ing to the chest radiograph [17]. Pneumonic exacerbations were associated with a lower arterial
oxygen (6.69 vs 7.57 kPa) and higher rates of invasive ventilation (17% vs 5%). There were no
significant differences in epidemiological factors between groups and prior use of ICS was not
evaluated. A UK audit of 9338 admissions with COPD also demonstrated an elevated relative
risk of mortality in the consolidation group during admission (relative risk 1.19 (1.01–1.42))
and within 90 days of follow up (relative risk 1.09 (0.96–1.23)) after adjusting for potential con-
founding factors [6].
Huerta et al. evaluated 133 patients with eCOPD and 116 cases with eCOPD and radiologi-
cal consolidation. Patients with consolidation had significantly higher serum levels of C-reac-
tive protein, procalcitonin, tumor necrosis factor-α and IL-6 and were more likely to present
with pleuritic pain and sputum purulence [7]. This suggests that a different pathophysiological
process underlies exacerbations which feature consolidation.
There was no correlation between previous ICS use and radiological consolidation in this
very large patient cohort. A Cochrane review reports that long term studies of patients on ICS
for COPD (those lasting more than six months) show an increased rate of pneumonia (OR
Fig 1. Kaplan-Meier curves comparing patients with and without consolidation. Black line represents patients with radiological consolidation. Grey line
represents patients without consolidation.
doi:10.1371/journal.pone.0134004.g001
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Table 6. Multilevel multivariate analysis of factors associated with global mortality.
Variable Categories Odds ratio 95% CI Lower limit 95% CI Upper limit
Tobacco history < 45 pack-yr 1
> 45 pack-yr 0.7108328 0.5439595 0.9288988
0 pack-yr 0.9765071 0.7485789 1.273835
Missing 1.108811 0.8487406 1.448573
Charlson 1.140256 1.095053 1.187324
Cardiovascular disease No 1
Yes 1.26089 1.110656 1.431445
Neoplasms No 1
Yes 1.32491 1.112268 1.578205
Body mass index (kg/m2) <19.5 1.521293 1.222735 1.89275
19.5–24.99 1
25–29.99 0.7467633 0.6158508 0.9055041
>29.99 0.5479803 0.4431545 0.677602
Missing 1.04239 0.8833963 1.229999
FEV1 > 50% 1
< 50% 2.262178 1.456364 3.513854
Missing 2.38802 1.657867 3.439746
GOLD 1 1
2 1.007983 0.5377207 1.889512
3 0.5496564 0.2582095 1.170066
4 0.8463124 0.3995143 1.792788
Missing 0.8034995 0.4005745 1.611714
Purulent sputum No 1
Yes 0.7753743 0.6852549 0.8773455
Missing 1.266613 1.06029 1.513083
pH  7.35 1
< 7.35 1.795053 1.569601 2.052888
Missing 0.8707558 0.5676513 1.335707
Consolidation No 1
Yes 1.366193 1.200809 1.554355
Ventilatory support correctly prescribed No 1
Yes 0.4327955 0.3670793 0.5102764
Missing 0.8639866 0.5549094 1.345216
Invasive mechanical ventilation No 1
Yes 3.001931 2.230816 4.039594
In-hospital antibiotics No 1
Yes 1.307474 1.099753 1.554429
In-hospital inhaled corticosteroids No
Yes 0.8655159 0.7617572 0.9834076
In-hospital diuretics No 1
Yes 1.592629 1.402293 1.808799
Number of recommendations 1.121738 1.049479 1.198971
Wald chi2 (28) = 798.31; Log likelihood = -4930.8825; Prob > chi2 < 0.0001.
White: patient related; light grey: exacerbation related; dark grey: management related. FEV1: forced expiratory volume in 1 second. GOLD: Global
Initiative for Obstructive Lung Disease spirometric classification.
doi:10.1371/journal.pone.0134004.t006
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1.56, 95%CI 1.30 to 1.86, 6235 participants) [13]. The evidence for this associated risk is great-
est for fluticasone at a dose of 1000 μg/day where the increased risk of pneumonia was found to
be 64% in the 3-year TORCH trial and 94% in the 2-year Investigating New Standards for Pro-
phylaxis in Reducing Exacerbations (INSPIRE) trial [19, 20]. The absence of a correlation
between ICS use and consolidation as described here is unlikely to be fully explained by hetero-
geneity of treatment duration and specific ICS used given the considerable size of the cohort. It
may be that pneumonia associated with ICS use in COPD patients is more likely to present as a
classical pneumonia picture with features of systemic sepsis and such patients were excluded
from this audit of eCOPD. This finding may impact on the decision to continue potentially
beneficial ICS treatment in patients with COPD presenting with exacerbations where consoli-
dation is present.
Point Of Inclusion, Strengths andWeaknesses, Future Directions
As previously stated, an important difference between this and similar studies is the point of
inclusion. This study used a clinician-made diagnosis of eCOPD as the criterion for recruit-
ment regardless of whether radiological consolidation is present. Patients with a discharge
diagnosis of pneumonia were excluded. Although these criteria were not strictly defined, the
emphasis was on overall clinical picture rather than solely radiological findings in diagnosing
eCOPD versus pneumonia.
There are a number of confounding factors in this study which are acknowledged. This is an
observational study which did not have this hypothesis as its primary endpoint. Subjects with
‘other’ radiological abnormalities were excluded to avoid contaminating the purely ‘consolida-
tion’ group but it may be that the reduction in cases for analysis arising as a consequence could
distort some results. The study excluded COPD patients admitted with a primary diagnosis of
pneumonia and is dependent upon clinicians categorizing patients appropriately. The selection
of subjects in this and the other existing studies quoted above vary considerably making close
comparisons difficult. A substantial proportion of the audit patients (40.9%) were missing spi-
rometric data which reflects difficulties in collecting a complete dataset of this size. Further-
more, 7.0% of patients had spirometry which did not demonstrate an obstructive FEV1/FVC
ratio and would not satisfy the spirometric diagnostic criteria for COPD. The inclusion of these
patients reflects real world practice where a COPD diagnosis is often made on clinical grounds.
Because of the nature of this dataset, potential variables of interest such as serum C-reactive
protein values or white blood cells and neutrophils counts, or the topography and features of
these consolidations were not recorded. There is a need for well-designed studies collecting
these extra data to perform different analytical approaches such as propensity-matched
scoring.
The considerable strengths of the study include its population size (14,111 cases, 2,714 with
consolidation) were drawn from 384 different hospitals across 13 European countries and are
very likely to reflect real life clinical practice. In this study we have demonstrated that there are
some relatively minor differences in characteristics between patients with and without radio-
logical consolidation presenting clinically as eCOPD. Patients with cardiovascular comorbidity
and a high frequency of previous exacerbations appear to be at higher risk of radiological con-
solidation complicating eCOPD. The key presentation differences are in the greater likelihood
of purulent sputum and more severe acidosis which should further prompt the clinician to
review the chest radiograph. Such patients should then receive appropriate antibiotic therapy
according to local and national guidelines. The finding that patients with consolidation are
more likely to receive ICU care and IMV is a further reason to recognize this patient group at
admission.
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Conclusions
The question of whether to redefine this group as ‘pneumonia’ and not eCOPD is one which
we suggest could only be definitively answered by a large scale prospective study with defined
subgroup definitions and outcomes. The increased reporting of minor degrees of radiological
‘shadowing’ and ‘consolidation’ from computed tomography (CT) [21] and CT pulmonary
angiograms in patients admitted with clinical diagnosis of eCOPD further complicates these
definitions. Until such studies are concluded we suggest that radiological consolidation compli-
cating eCOPD is recognized as a subgroup of patients requiring particular management in the
same way as do those without evidence of infection and those with bronchial infection alone.
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